Skip to main content
MyPeptideDosagesMyPeptideDosages
single20MG

Vilon

20MG Protocol

Vilon 20MG

Injection Freq.

Once per day (subcutaneous) for 5 consecutive days per cycle

Cycle Sched.

5 days on, ~23 days off (4‑week cycle); run 2–4 cycles

Reconstitution

3.0 mL BAC water

Supports immune-marker and cytokine-gene activity in cell-culture models (CD5+, IL-2)
Potential modulation of inflammatory signaling pathways in preclinical renal models
Early mouse studies referenced suggest tumor-growth inhibition and lifespan-extension signals (limited human relevance)
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1+67 mcg (0.067 mg)1
2Weeks 1+133 mcg (0.133 mg)2
3Weeks 1+200 mcg (0.20 mg)3
4Weeks 1+267 mcg (0.267 mg)4
5Weeks 1+333 mcg (0.33 mg)5
6Weeks 1+333–667 mcg (0.33–0.67 mg)10

Once per day (subcutaneous) for 5 consecutive days per cycle

5 days on, ~23 days off (4‑week cycle); run 2–4 cycles

Vilon (Lys–Glu) is presented as a short ‘bioregulatory’ peptide developed in the context of Russian gerontology research. The protocol’s mechanism section emphasizes in vitro immunomodulatory findings rather than a single receptor target. Specifically, Vilon is described as influencing lymphocyte markers and cytokine gene expression: studies cited on the page report increased CD5+ cell counts in thymus cell cultures and increased interleukin-2 (IL-2) mRNA expression in splenocyte preparations. Additional preclinical observations referenced include potential effects on inflammatory signaling (e.g., TGF-β1) and vascular permeability in renal models under experimental stress. The protocol also explains its pulsed schedule (a short 5-day series repeated on a monthly cycle) as analogous to other short-peptide regimens used in related research traditions. Overall, Vilon is positioned as an investigational immune-signaling modulator with limited direct human clinical characterization.
Mild injection-site reactions (redness/itching)
Limited human clinical data
evidence base described as preclinical/in vitro
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)

Related peptide protocols

More research-backed dosing guides in this category.